Abstract

This proposal presents a binary system for the treatment of cancer using boron neutron capture therapy (BNCT). Boron-10, when activated by thermal neutrons, produces a fission reaction yielding highly destructive alpha particles. Incorporation of sufficient boron into structures that have a proclivity for melanoma cells is described. Monoclonal antibodies directed against melanoma-associated antigens will be covalently linked to boron-containing macromolecules. These together with other tumor-localizing compounds such as boron-containing chlorpromazine and porphyrins, either alone or in combination will be evaluated for their ability to deliver a critical number of boron-10 atoms (about 10-9) per cell and sustain a lethal n,Alpha reaction in vitro. Once this has been established, their in vivo tumor localizing properties will be determined in melanoma-bearing mice. These studies will lay the ground work for chemoradiotherapeutic trials in animals.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA041288-01A1
Application #
3181625
Study Section
Medicinal Chemistry Study Section (MCHA)
Project Start
1986-09-01
Project End
1989-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
Ohio State University
Department
Type
Schools of Pharmacy
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210

  Publications

Tzeng, J J; Barth, R F; Orosz, C G (1992) Quantitation of glioma-reactive cytolytic T lymphocyte precursors by means of limiting dilution analysis. J Immunol Methods 146:177-84
Oredipe, O A; Barth, R F; Rotaru, J H et al. (1992) Lack of effect of recombinant human interferon-alpha 2b on expression of 17-1A antigen on human colon cancer cells. Hybridoma 11:607-15
Barth, R F; Adams, D M; Soloway, A H et al. (1991) Determination of boron in tissues and cells using direct-current plasma atomic emission spectroscopy. Anal Chem 63:890-3
Tzeng, J J; Barth, R F; Orosz, C G et al. (1991) Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 51:2373-8
Tzeng, J J; Barth, R F; Johnson, C W et al. (1990) Distinct and non-cross-reactive epitopes are recognized on B16 melanoma by LAK cells and anti-B16 monoclonal antibodies. Proc Soc Exp Biol Med 193:285-92
Oredipe, O A; Barth, R F; Rotaru, J H et al. (1990) Alterations in monoclonal antibody affinity and antigenic receptor site expression on mycoplasma-infected human colorectal cancer cells. Proc Soc Exp Biol Med 194:301-7
Barth, R F; Soloway, A H; Fairchild, R G (1990) Boron neutron capture therapy of cancer. Cancer Res 50:1061-70
Soloway, A H; Alam, F; Barth, R F et al. (1990) Tumor targeting agents for neutron capture therapy. Basic Life Sci 54:37-47
Alam, F; Soloway, A H; Bapat, B V et al. (1989) Boron compounds for neutron capture therapy. Basic Life Sci 50:107-11
Barth, R F; Soloway, A H; Alam, F et al. (1989) Pre-clinical studies on boron neutron capture therapy. Basic Life Sci 50:95-105

Showing the most recent 10 out of 12 publications